



**Annual Conference of the Cancer Molecular Therapeutics
Research Association
July 23-27, 2023
Watkins Glen Harbor Hotel – Watkins Glen, NY**

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

Lodging, meals and conference will be at Watkins Glen Harbor Hotel, Watkins Glen, NY

SUNDAY – JULY 23RD

4:00 – 6:00 pm	Arrival and check-in
6:00 – 7:00 pm	<u>Dinner</u>
7:30 – 7:45 pm	Welcome / Introductory Remarks Martin McMahon, Huntsman Cancer Institute and Department of Dermatology, University of Utah, Salt Lake City, Utah President CMTRA
7:45 – 8:45 pm	KEYNOTE SPEAKER Piro Lito, Memorial Sloan Kettering
9:00 pm –	Opening reception

MONDAY – JULY 24TH

7:30 – 8:15 am	<u>Breakfast</u>
8:30 – 12:00 pm	MORNING SESSION: Targeting RAS Discussion Leader: Shiva Malek
8:30 – 8:45 am	Introduction





- 8:45 – 9:15 am “Targeting RAS-driven PIK3CA activation in human tumors”
Pedro Beltran, BridgeBio
- 9:15 – 9:40 am **Discussion**
- 9:40 – 10:00 am **Coffee Break**
- 10:00 – 10:30 am “Directly Targeting RAS: Lessons from Tri-Complex RAS-GTP Inhibitors”
Mallika Singh, Revolution Medicines
- 10:30 – 10:55 am **Discussion**
- 11:00 – 11:30 am **Martin McMahon, Huntsman Cancer Institute & Dept. of Dermatology, University of Utah**
- 11:30 – 11:55 am **Discussion**
- 12:00 – 1:00 pm **Lunch**
- 1:00 – 4:45 pm **OPEN NETWORKING AFTERNOON WITH OPTIONAL ACTIVITIES**
- 5:00 – 6:30 pm **Short Presentations from Abstracts, with Social**
- 5:00 – 5:15 pm “Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors”
Annapoorna Venkatachalam, Mayo Clinic
- 5:15 – 5:30 pm “Target identification and validation with clickable photoaffinity probes for LBL1 and betulinic acid”
Bingbing Li, OHSU
- 5:30 – 5:45 pm “c-MYC Mediated Resistance to Trametinib and 3 Hydroxychloroquine in Pancreatic Cancer is Overcome by CDK4/6 4 and Lysosomal Inhibition”
Conan Kinsey, Huntsman Cancer Institute
- 5:45 – 6:00 pm “Topical PHT-427 a dual AKT and PDK1 pleckstrin homology (PH) domain inhibitor for treatment of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma”
Garrett Booher, PHusis Therapeutics
- 6:00 – 6:30pm Social continues
- 6:30 – 7:30 pm **Dinner**
- 7:30 – 9:45 pm **EVENING SESSION: Targeting Autophagy**
Discussion Leader: Martin McMahon
- 7:30 – 7:45 pm **Introduction**





- 7:45 – 8:15 pm “Role of Autophagy in Cancer”
Eileen White, Rutgers Cancer Institute of New Jersey
- 8:15 – 8:45 pm **Discussion**
- 8:45 – 9:15 pm “Role of Autophagy in Cancer. Therapeutic Opportunities with First-in-Class ULK inhibitor DCC-3116”
Daniel L. Flynn, Deciphera Pharmaceuticals
- 9:15 – 9:45 pm **Discussion**
- 9:45 pm – **Social and Cocktail Hour**

TUESDAY – JULY 25TH

- 7:30 – 8:15 am **Breakfast**
- 8:30 – 12:00 pm **MORNING SESSION: Target ID and Discovery**
Discussion Leader: Cory Johannessen
- 8:30 – 8:45 am **Introduction**
- 8:45 – 9:15 am “Target Discovery in the Post-CRISPR Era”
Cory Johannessen, NIBR Oncology
- 9:15 – 9:40 am **Discussion**
- 9:40 – 10:00 am **Group Picture and Coffee Break**
- 10:00 – 10:30 am “Target Discovery in Pediatric Neuro-Oncology”
Pratiti (Mimi) Bandopadhyay, Dana-Farber Harvard Cancer Center
- 10:30 – 10:55 am **Discussion**
- 11:00 – 11:30 am “In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer”
Robert Manguso, Massachusetts General Hospital Center for Cancer Research
- 11:30 – 12:00 pm **Discussion**
- 12:00 – 1:00 pm **Lunch**
- 1:00 – 4:45 pm **OPEN NETWORKING AFTERNOON WITH OPTIONAL ACTIVITIES**
- 5:30 – 6:30 pm **Social Hour**
- 6:30 – 7:30 pm **Dinner**





7:30 – 9:45 pm	EVENING SESSION: Pediatric Brain Cancers Discussion Leader: Peter Houghton
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	“A new paradigm to exploit DDR defects in glioma and beyond” Ranjit Bindra, Yale School of Medicine
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	“Beyond MEK Inhibitors for Treatment of Pediatric Glioma” Peter Houghton
9:15 – 9:40 pm	Discussion
9:40 pm –	<u>Social and Cocktail Hour</u>

WEDNESDAY – JULY 26TH

7:30 – 8:15 am	<u>Breakfast</u>
8:30 – 12:00 pm	MORNING SESSION: Targeting the Cell Cycle Discussion Leader: Bob Abraham
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“Activating CDK1 as a therapeutic strategy” Dan Durocher, University of Toronto
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<u>Coffee Break</u>
10:00 – 10:30 am	“Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity” Sabrina Spencer, University of Colorado Boulder
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Targeting cyclin-dependent kinases in Breast Cancer and beyond” Astrid Ruefli-Brasse, Pfizer
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<u>Lunch</u>
1:00 – 2:00pm	Break





- 2:00 – 2:45 pm **Short presentations from Abstracts**
- 2:00 – 2:15 pm “LP-184, a clinical-stage small molecule, is a potent inducer of synthetic lethality and has broad potential beyond HRD tumors”
Kishor Bhatia, Lantern Pharma
- 2:15 – 2:30 pm “Cells rapidly adapt to CDK2 inhibition via plasticity of the Rb-E2F axis”
Lotte Watts, University of Colorado-Boulder
- 2:30 – 2:45 pm “Genome Stability Maintenance during Cellular Quiescence through CDT1 Regulation”
Robert H. Whitaker, UNC Chapel Hill
- 2:50 – 3:05 pm “A randomized, placebo-controlled, first in human phase I single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy male volunteers of the immunostimulant 7HP349”
Lionel D. Lewis, 7 Hills Pharma LLC
- 3:05 – 3:10pm **Break**
- 3:10 – 5:30 pm **AFTERNOON SESSION: Cyclic Peptide/Macrocyces Chemistry**
Discussion Leader: Eli Wallace
- 3:10 – 3:15 pm **Introduction**
- 3:15 – 3:45 pm “Cyclin A/B RxL macrocyclic inhibitors are synthetic lethal in Rb/E2F pathway dysfunctional cancer”
Catherine Gleason, Circle Pharma
- 3:45 -4:10 pm **Discussion**
- 4:10 – 4:40 pm “Rings to rule them all: macrocyclic peptides as an emerging therapeutic modality for intracellular protein-protein interactions”
Cameron Pye, Unnatural Products
- 4:45 – 5:10 pm **Discussion**
- 6:30 – 10:00 pm ***Farewell Dinner and Reception***

THURSDAY – JULY 27TH

7:30 – 8:15 am **Breakfast**






CMTRA
The Cancer Molecular Therapeutics
Research Association

11:00 am

CHECK OUT BY 11:00 AM

THIS MEETING WOULD NOT BE POSSIBLE WITHOUT THE GENEROUS CONTRIBUTIONS
FROM OUR MANY FRIENDS AND COLLEAGUES:



CANCER MOLECULAR THERAPEUTICS OF RESEARCH ANNUAL CONFERENCE 2023

